These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 11942169)

  • 1. [Adjuvant treatment of prostatic carcinoma after primary therapy. The "Early Prostate Cancer" Program].
    Mansueto G; Longo F
    Recenti Prog Med; 2002 Mar; 93(3):175-8. PubMed ID: 11942169
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adjuvant hormone therapy in prostatic cancer: after treatment with curative intent. The viewpoint of the urologist].
    Martorana G
    Recenti Prog Med; 2002 Mar; 93(3):179-82. PubMed ID: 11942170
    [No Abstract]   [Full Text] [Related]  

  • 3. [Efficacy of bicalutamide in adjuvant treatment of prostatic carcinoma after primary therapy with curative aim. The viewpoint of the surgeon].
    Rigatti P; Scattoni V
    Recenti Prog Med; 2002 Mar; 93(3):183-5. PubMed ID: 11942171
    [No Abstract]   [Full Text] [Related]  

  • 4. [Preliminary results of casodex use in patients with hormone-resistant cancer of the prostate].
    Matveev BP; Bukharkin BV
    Urologiia; 2001; (6):20-1. PubMed ID: 11785074
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hormonal treatment of cancer of the prostate: review and present status].
    Ganzer R; Wieland WF; Bach T; Rössler W; Blana A
    Dtsch Med Wochenschr; 2007 Jan; 132(4):161-6. PubMed ID: 17230333
    [No Abstract]   [Full Text] [Related]  

  • 6. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Early Prostate Cancer program: bicalutamide in nonmetastatic prostate cancer.
    Iversen P; Roder MA
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):361-9. PubMed ID: 18366284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Reevaluation of MAB therapy and progress of endocrine therapy].
    Klotz L; Payne H; Gillatt D; Keane T; Morris C; Akaza H; Hirao ; Akakura K; Fukagai T
    Gan To Kagaku Ryoho; 2005 May; 32(5):705-28. PubMed ID: 15934164
    [No Abstract]   [Full Text] [Related]  

  • 10. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients with prostate cancer: the role of tamoxifen and radiotherapy.
    Di Lorenzo G; Perdonà S; De Placido S; D'Armiento M; Gallo A; Damiano R; Pingitore D; Gallo L; De Sio M; Autorino R
    J Urol; 2005 Dec; 174(6):2197-203. PubMed ID: 16280763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monotherapy with casodex at a dose of 150 mg--a new method of hormonal treatment of disseminated prostatic cancer].
    Rusakov IG; Alekseev BIa
    Urologiia; 2002; (5):23-6. PubMed ID: 12402771
    [No Abstract]   [Full Text] [Related]  

  • 12. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
    Morote J; Orsola A; Planas J; Trilla E; Raventós CX; Cecchini L; Catalán R
    J Urol; 2007 Oct; 178(4 Pt 1):1290-5. PubMed ID: 17698136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in prostate-specific antigen in casodex (bicalutamide) monotherapy in a dose 150 mg/day given to patients with locally advanced and/or advanced prostatic cancer].
    Kariakin OB; Sviridova TV; Tsodikova LB; Grishin GN; Sergeeva TN; Perekhrest MA; Donichkina EA
    Urologiia; 2001; (4):26-9. PubMed ID: 11569230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drug for prostate cancer.
    Eur J Cancer Care (Engl); 2001 Jun; 10(2):79-80. PubMed ID: 11829051
    [No Abstract]   [Full Text] [Related]  

  • 16. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dutasteride and bicalutamide in patients with hormone-refractory prostate cancer: the Therapy Assessed by Rising PSA (TARP) study rationale and design.
    Sartor O; Gomella LG; Gagnier P; Melich K; Dann R
    Can J Urol; 2009 Oct; 16(5):4806-12. PubMed ID: 19796455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monotherapy with antiandrogens for prostatic cancer].
    Sander S
    Tidsskr Nor Laegeforen; 1999 Apr; 119(10):1451-3. PubMed ID: 10354754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A new anti-androgen, bicalutamide (Casodex), for the treatment of prostate cancer--basic clinical aspects].
    Akaza H
    Gan To Kagaku Ryoho; 1999 Jul; 26(8):1201-7. PubMed ID: 10431591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.